• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Kura Oncology Inc.

    3/21/25 4:21:02 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KURA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001352620
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    KURA ONCOLOGY INC
    SEC File Number
    001-37620
    Address of Issuer
    12730 High Bluff Drive, Suite 400
    San Diego
    CALIFORNIA
    92130
    Phone
    8585008800
    Name of Person for Whose Account the Securities are To Be Sold
    FAHEEM HASNAIN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    30000235500.008075496103/21/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/21/2025Exercise of Stock OptionsIssuerCheckbox not checked3000003/21/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
    Date of Notice
    03/21/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/20/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Faheem Hasnain

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $KURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KURA

    DatePrice TargetRatingAnalyst
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    5/17/2023$31.00Buy
    BTIG Research
    1/31/2023$25.00Buy
    Stifel
    More analyst ratings

    $KURA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kura Oncology Inc.

      10-Q - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:15:19 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:10:11 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Kura Oncology Inc.

      DEF 14A - Kura Oncology, Inc. (0001422143) (Filer)

      4/11/25 4:50:53 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Kura Oncology Inc.

      SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

      12/5/24 6:55:37 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:31:29 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:32:22 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kura Oncology to Participate in Bank of America Securities Healthcare Conference

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event. About Kura Oncology Kura Oncology is a clinical-stage biopharm

      5/6/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 433,950 shares of common stock to sixteen (16) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listi

      5/2/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Financials

    Live finance-specific insights

    See more
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report First Quarter 2025 Financial Results

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and

      4/24/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

      – KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference

      2/26/25 4:03:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hasnain Faheem exercised 22,682 shares at a strike of $6.32 and sold $181,456 worth of shares (22,682 units at $8.00) (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      3/24/25 4:33:39 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Finance & Accounting Doyle Thomas James sold $38,958 worth of shares (4,949 units at $7.87), decreasing direct ownership by 5% to 88,193 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:54:15 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Leoni Mollie sold $39,068 worth of shares (4,963 units at $7.87), decreasing direct ownership by 5% to 88,253 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:39:01 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kura Oncology downgraded by BTIG Research

      BTIG Research downgraded Kura Oncology from Buy to Neutral

      2/6/25 7:53:07 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Kura Oncology with a new price target

      UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00

      10/24/24 6:23:30 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology downgraded by Stifel with a new price target

      Stifel downgraded Kura Oncology from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      10/14/24 7:36:13 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

      SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff

      9/17/24 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Appoints Brian Powl as Chief Commercial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products. "Brian is an accomplished leader with a strong track record in building successful commercial organizations and driving global commercial

      8/14/23 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care